Japan Proton Therapy Market Report 2022: Featuring IBA Proton Therapy, Varian Medical Systems & Elekta – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Japan Proton Therapy Market, Share, Forecast 2022-2027, Industry Trends, Growth, Size, Impact of COVID-19, Company Analysis” report has been added to ResearchAndMarkets.com’s offering.

The Japan Proton Therapy Market value will be US$ 8.6 Billion by 2027. Over the years, various techniques for cancer treatment have emerged, such as chemotherapy, surgery, and proton therapy. The proton therapy is the new technology and is expected to least impair the quality of life compared to other forms of treatment.

Japan has one of the highest numbers of proton therapy treatment clinics globally. The improving cutting-edge technology in radiotherapy and growing technological development in Japan will further drive the proton therapy industry in the future.

Japan Proton Therapy Potential Market Size was US$ 6.1 Billion post-pandemic recoveries in 2021

The growth of the proton therapy market in Japan is mainly driven by rising healthcare expenditure, expanding preference for advanced therapies by healthcare practitioners, increasing confirmation, and increasing cancer pervasiveness. Another outstanding growth driver is the faster uptake and access and premium pricing. As these systems become more widespread, they are likely to require further refinement and enhancement to respond to the needs of medical staff.

Cancer Types – Market Segmentation

Based on Cancer Types, the proton therapy market of Japan is further segmented into Central Nervous System (CNS) Tumors, Head and Neck Cancer, Lung Cancer, GI (Gastro-Intestinal) Cancer, Hepatocellular Carcinoma (HCC) Cancer, Pancreas Cancer, Gynecologic Cancers, Prostate Cancer, Bone, and Soft Tissue Cancer and Other Cancer. According to the publisher report, Japan Proton Therapy Industry is expected to grow with a CAGR of 5.9% during 2021-2027.

Besides, proton therapy applications are more inclined towards Gastrointestinal Tract Cancer and lung cancer due to references by healthcare specialists. Moreover, proton therapy is also recognized to be comparatively safer in the case of patients with central nervous system (CNS) tumors.

Although there is less experience with proton therapy combined with chemotherapy for pancreatic cancer, favorable outcomes have been reported recently in Japan. Remarkably, these applications are anticipated to drive the revenue for the proton therapy industry over the forecast period.

Cancer Types – Japan Proton Therapy Number of Patients have been covered from 10 viewpoints:

1. Central Nervous System (CNS) Tumors

2. Head and Neck Cancer

3. Lung Cancer

4. GI (Gastro-Intestinal) Cancer

5. Hepatocellular Carcinoma (HCC) Cancer

6. Pancreas Cancer

7. Gynecologic Cancers

8. Prostate Cancer

9. Bone and Soft Tissue Cancer

10. Others Cancer

Cancer Types – Japan Proton Therapy Market have been covered from 10 viewpoints:

1. Central Nervous System (CNS) Tumors

2. Head and Neck Cancer

3. Lung Cancer

4. GI (Gastro-Intestinal) Cancer

5. Hepatocellular Carcinoma (HCC) Cancer

6. Pancreas Cancer

7. Gynecologic Cancers

8. Prostate Cancer

9. Bone and Soft Tissue Cancer

10. Others Cancer

All companies have been covered from 3 viewpoints:

• Overview
• Recent Developments
• Sales Analysis

Key Topics Covered:

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

5. Japan Proton Therapy Market (Actual & Untapped)

6. Number of Patients – Japan Proton Therapy

7. Cancer Types – Japan Proton Therapy Number of Patients

8. Cancer Types – Japan Proton Therapy Market

9. Japan – List of Proton Therapy Centers

10. Reimbursement Policies – Japan Proton Therapy

11. Components of a Standard Proton Therapy Center

12. Porters Five Forces

13. Company Analysis

Companies Mentioned

• IBA Proton Therapy
• Varian Medical Systems
• Elekta

For more information about this report visit https://www.researchandmarkets.com/r/xudjkm

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900